Document Detail

Efficacy of levosimendan in patients with chronic heart failure: Does rhythm matter?
MedLine Citation:
PMID:  20693125     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Levosimendan is a relatively new inotropic agent. Unlike other inotropic agents, Levosimendan does not increase cellular calcium intake, so that, does not cause intracellular calcium overload and related arrhythmias. Atrial fibrillation (AF) was shown to be an independent risk factor for mortality and morbidity in large heart failure (HF) trials. Heart failure induces AF, AF aggravates HF and therefore they generally coexist. We conducted a study to investigate if there is any differential effect of Levosimendan in HF patients with chronic AF and without AF.
METHODS: This is a prospective study. Consecutive patients, who were hospitalized because of acutely decompensated HF due to systolic dysfunction and decided Levosimendan administration, were enrolled. Patients were classified into two as those with AF (group A) and those with sinus rhythm (control group, group S). All patients had echocardiography before and after administration. Echocardiographic data were evaluated by ANOVA repeated measurements test.
RESULTS: Baseline left ventricle ejection fraction (LVEF) was poorer in group with AF (mean LVEF for group A: 20.9%, for group S: 26.4%, p=0.04). Baseline diastolic parameters were equally impaired. After infusion, diastolic parameters like velocity of propagation (Vp) and isovolumic relaxation time (IVRT) improved almost to same extent in both groups but deceleration time (DT) did not. IVRT values decreased (p=0.012) both in group S (from 108.6+/-23.2 msec to 100.4+/-28.4 msec) and group A (from 117.3+/-25.1 msec to 92.0+/-20.9 msec) without a significant difference between groups (p=0.180 for interaction). Another valuable diastolic parameter, Vp was also similarly improved (p=0.01) in both groups to similar extent (for group A, from 35.4+/-8.8 cm/sec to 41.1+/-7.7 cm/sec, for group S, from 33.7+/-7.5 cm/sec to 37.8+/-7.6 cm/sec; p=0.498 for interaction).
CONCLUSION: We have shown that in patients with chronic HF and AF, levosimendan improves left ventricular systolic and diastolic functions as good as those with HF and sinus rhythm. We suggest that a positive electrophysiological effect of levosimendan on failing myocardial tissue seems to fill the absence of atrial booster in patients with AF who are on beta-blocker therapy.
Osman Can Yontar; Mehmet Birhan Yilmaz; Kenan Yalta; Izzet Tandoğan
Related Documents :
18807225 - Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician.
19860685 - Pathophysiological insights into atrial fibrillation following cardiac surgery: implica...
11755375 - Does the progression of myocardial fibrosis lead to atrial fibrillation in patients wit...
11216975 - Different patterns of atrial activation in idiopathic atrial fibrillation: simultaneous...
9240885 - Clinical and echocardiographic evaluation of neonates with heart murmurs.
3075405 - Study of the effect of tensiomin (captopril) in chronic heart failure.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology     Volume:  10     ISSN:  1308-0032     ISO Abbreviation:  Anadolu Kardiyol Derg     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-08-09     Completed Date:  2010-12-22     Revised Date:  2011-07-19    
Medline Journal Info:
Nlm Unique ID:  101095069     Medline TA:  Anadolu Kardiyol Derg     Country:  Turkey    
Other Details:
Languages:  eng     Pagination:  310-6     Citation Subset:  IM    
Department of Cardiology, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Atrial Fibrillation / complications,  drug therapy
Cardiotonic Agents / administration & dosage,  therapeutic use*
Diastole / drug effects
Heart Failure / complications,  drug therapy*,  etiology
Heart Rate / drug effects
Hydrazones / administration & dosage,  therapeutic use*
Infusions, Intravenous
Middle Aged
Prospective Studies
Pyridazines / administration & dosage,  therapeutic use*
Stroke Volume / drug effects
Reg. No./Substance:
0/Cardiotonic Agents; 0/Hydrazones; 0/Pyridazines; 131741-08-7/simendan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The variations of BOP gene in hypertrophic cardiomyopathy.
Next Document:  Plasma renin activity and pro-B-type natriuretic peptide levels in different atrial fibrillation typ...